pre-IPO PHARMA

COMPANY OVERVIEW

Revalesio Corporation, located in Tacoma, WA, is partnering with leaders in biomedical research around the globe to harness the benefits of fluid modification via turbulent Taylor-Couette-Poiseuille (TCP) flow. Revalesio’s patented application of fluid cavitation within a TCP flow environment has resulted in ground breaking publications in the disciplines of physical chemistry as well as biomedical science.


LOCATION

  • Tacoma, WA, USA

  • THERAPEUTIC AREAS

  • Inflammatory Disease
  • Neurological DIsorders

  • WEBSITE

    https://revalesio.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Feb 18, 2022

    Revalesio Announces the Design of RESCUE, a Phase 2 Trial of RNS60 in Acute Ischemic Stroke, and the Presentation of Preclinical Data at the International Stroke Conference 2022


    Dec 7, 2021

    Promising Clinical Data on Revalesio’s RNS60 Presented at 32nd International Symposium on ALS/MND


    Nov 18, 2013

    Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions


    Nov 11, 2013

    Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich


    Jan 3, 2013

    Revalesio's RNS60 Protects Myelin and Halts Multiple Sclerosis in Mice


    For More Press Releases


    Google Analytics Alternative